These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 24587245)

  • 21. Mutations in BRCA2 and taxane resistance in prostate cancer.
    Nientiedt C; Heller M; Endris V; Volckmar AL; Zschäbitz S; Tapia-Laliena MA; Duensing A; Jäger D; Schirmacher P; Sültmann H; Stenzinger A; Hohenfellner M; Grüllich C; Duensing S
    Sci Rep; 2017 Jul; 7(1):4574. PubMed ID: 28676659
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Acquired resistance to PRMT5 inhibition induces concomitant collateral sensitivity to paclitaxel.
    Mueller HS; Fowler CE; Dalin S; Moiso E; Udomlumleart T; Garg S; Hemann MT; Lees JA
    Proc Natl Acad Sci U S A; 2021 Aug; 118(34):. PubMed ID: 34408017
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Silencing stathmin-modulating efficiency of chemotherapy for esophageal squamous cell cancer with paclitaxel.
    Feng W; Xiaoyan X; Xuan Y; Xiangke L; Zichang Y; Ran Z; Liuxing W; Qingxia F
    Cancer Gene Ther; 2015 Apr; 22(3):115-21. PubMed ID: 25572118
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Elevated STMN1 promotes tumor growth and invasion in endometrial carcinoma.
    He X; Liao Y; Lu W; Xu G; Tong H; Ke J; Wan X
    Tumour Biol; 2016 Jul; 37(7):9951-8. PubMed ID: 26815505
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Taxane-containing regimens for metastatic breast cancer.
    Ghersi D; Willson ML; Chan MM; Simes J; Donoghue E; Wilcken N
    Cochrane Database Syst Rev; 2015 Jun; 2015(6):CD003366. PubMed ID: 26058962
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Enhancement of Chemosensitivity by Stathmin-1 Silencing in Gastric Cancer Cells In Situ and In Vivo.
    Meng ZJ; Tao K
    Oncol Res; 2016 Jan; 23(1-2):35-41. PubMed ID: 26802649
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Genetic association with overall survival of taxane-treated lung cancer patients - a genome-wide association study in human lymphoblastoid cell lines followed by a clinical association study.
    Niu N; Schaid DJ; Abo RP; Kalari K; Fridley BL; Feng Q; Jenkins G; Batzler A; Brisbin AG; Cunningham JM; Li L; Sun Z; Yang P; Wang L
    BMC Cancer; 2012 Sep; 12():422. PubMed ID: 23006423
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Overexpression of stathmin is resistant to paclitaxel treatment in patients with non-small cell lung cancer.
    Sun R; Liu Z; Wang L; Lv W; Liu J; Ding C; Yuan Y; Lei G; Xu C
    Tumour Biol; 2015 Sep; 36(9):7195-204. PubMed ID: 25894372
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Superior antitumor activity of nanoparticle albumin-bound paclitaxel in experimental gastric cancer.
    Zhang C; Awasthi N; Schwarz MA; Hinz S; Schwarz RE
    PLoS One; 2013; 8(2):e58037. PubMed ID: 23460921
    [TBL] [Abstract][Full Text] [Related]  

  • 30. TLE3 is not a predictive biomarker for taxane sensitivity in the NCIC CTG MA.21 clinical trial.
    Bartlett JM; Nielsen TO; Gao D; Gelmon KA; Quintayo MA; Starczynski J; Han L; Burnell MJ; Levine MN; Chen BE; Shepherd LE; Chapman JW;
    Br J Cancer; 2015 Sep; 113(5):722-8. PubMed ID: 26284338
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Smoothened antagonists reverse taxane resistance in ovarian cancer.
    Steg AD; Katre AA; Bevis KS; Ziebarth A; Dobbin ZC; Shah MM; Alvarez RD; Landen CN
    Mol Cancer Ther; 2012 Jul; 11(7):1587-97. PubMed ID: 22553355
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Fibroblast growth factor receptor inhibition synergizes with Paclitaxel and Doxorubicin in endometrial cancer cells.
    Byron SA; Loch DC; Pollock PM
    Int J Gynecol Cancer; 2012 Nov; 22(9):1517-26. PubMed ID: 23060048
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A combination of paclitaxel and siRNA-mediated silencing of Stathmin inhibits growth and promotes apoptosis of nasopharyngeal carcinoma cells.
    Wu Y; Tang M; Wu Y; Weng X; Yang L; Xu W; Yi W; Gao J; Bode AM; Dong Z; Cao Y
    Cell Oncol (Dordr); 2014 Feb; 37(1):53-67. PubMed ID: 24306928
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Lx2-32c, a novel taxane derivative, exerts anti-resistance activity by initiating intrinsic apoptosis pathway in vitro and inhibits the growth of resistant tumor in vivo.
    Zhou Q; Li Y; Jin J; Lang L; Zhu Z; Fang W; Chen X
    Biol Pharm Bull; 2012; 35(12):2170-9. PubMed ID: 23207769
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Multi-gene expression predictors of single drug responses to adjuvant chemotherapy in ovarian carcinoma: predicting platinum resistance.
    Ferriss JS; Kim Y; Duska L; Birrer M; Levine DA; Moskaluk C; Theodorescu D; Lee JK
    PLoS One; 2012; 7(2):e30550. PubMed ID: 22348014
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Stathmin is a marker of progression and poor prognosis in esophageal carcinoma.
    Wang F; Xuan XY; Yang X; Cao L; Pang LN; Zhou R; Fan QX; Wang LX
    Asian Pac J Cancer Prev; 2014; 15(8):3613-8. PubMed ID: 24870766
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [A Case of Taxane-Pretreated Metastatic Gastric Cancer with Excellent Response to Nab-Paclitaxel].
    Kawabata R; Kimura Y; Kawase T; Yoshikawa M; Kameda C; Matsumura T; Koga C; Murakami M; Hirota M; Noura S; Ikenaga M; Shimizu J; Hasegawa J
    Gan To Kagaku Ryoho; 2015 Nov; 42(12):2088-90. PubMed ID: 26805273
    [TBL] [Abstract][Full Text] [Related]  

  • 38. SIRT5 as a biomarker for response to anthracycline-taxane-based neoadjuvant chemotherapy in triple-negative breast cancer.
    Xu L; Che X; Wu Y; Song N; Shi S; Wang S; Li C; Zhang L; Zhang X; Qu X; Teng Y
    Oncol Rep; 2018 May; 39(5):2315-2323. PubMed ID: 29565454
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Survival analysis of carboplatin added to an anthracycline/taxane-based neoadjuvant chemotherapy and HRD score as predictor of response-final results from GeparSixto.
    Loibl S; Weber KE; Timms KM; Elkin EP; Hahnen E; Fasching PA; Lederer B; Denkert C; Schneeweiss A; Braun S; Salat CT; Rezai M; Blohmer JU; Zahm DM; Jackisch C; Gerber B; Klare P; Kümmel S; Schem C; Paepke S; Schmutzler R; Rhiem K; Penn S; Reid J; Nekljudova V; Hartman AR; von Minckwitz G; Untch M
    Ann Oncol; 2018 Dec; 29(12):2341-2347. PubMed ID: 30335131
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The Impact of Eribulin on Stathmin Dynamics and Paclitaxel Sensitivity in Ovarian Cancer Cells.
    Azumi M; Yoshie M; Takano W; Ishida A; Kusama K; Tamura K
    Biol Pharm Bull; 2022; 45(11):1627-1635. PubMed ID: 36328498
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.